Head to head

CJC-1295 with DAC vs Ipamorelin

GH secretagogue

Two compounds that are more often stacked than compared — the side-by-side data, and what actually separates them.

Verdict

Not an either/or

CJC-1295 with DAC and Ipamorelin appear in each other's stacks in this dataset, so the most common real-world use is together rather than instead of. If you do have to pick one, let route and schedule decide it — CJC-1295 with DAC is subcutaneous, once a week; Ipamorelin is subcutaneous, once daily — because the evidence does not separate them cleanly enough to do it for you.

What you are actually choosing between

Before anything else: the dataset lists CJC-1295 with DAC and Ipamorelin in each other's stacks. They are run together more often than they are chosen between, so if you came here for a winner, the first honest answer is that this may not be an either/or.

Both are classed here as growth hormone secretagogues, so this is a within-class choice: the mechanism is broadly shared and what separates them is kinetics, route, and how much has actually been tested.

The overlap is muscle growth, recovery and sleep, and injury repair. On this site's goal weighting — an editorial priority score, not a measure of effect size — CJC-1295 with DAC rates 4/5 for muscle growth and Ipamorelin rates 3/5.

The evidence

Neither has an evidence edge — both sit at the same tier. CJC-1295 with DAC: some human data, but it is small, old, or uncontrolled; phase 1 single-dose studies only; development was discontinued. Ipamorelin: some human data, but it is small, old, or uncontrolled; small early-phase work only; development was discontinued. Anyone telling you one is clearly better supported than the other is going beyond what is published.

How they differ in practice

Kinetics are not close. CJC-1295 with DAC has a half-life of 7 days against Ipamorelin's 2 h — roughly 84× — which is why one is dosed once a week and the other once daily. A long half-life means a steadier level and a mistake you cannot take back for days; a short one means timing matters and a bad day washes out fast.

Risk and difficulty

Ipamorelin is rated beginner here and CJC-1295 with DAC intermediate. That rating is about how much can go wrong in handling, dosing and monitoring, not about how well either works.

Source notes

What the evidence actually says

Verbatim, so you can check the verdict above against what it was built from.

CJC-1295 with DAC

Dosed once weekly at 1 to 2 mg, which is how it is overwhelmingly run in practice: the albumin binding makes the weekly total the meaningful quantity, and splitting it across the week buys nothing. A GHRH (1-29) analogue carrying a Drug Affinity Complex maleimide that binds serum albumin, which is the ONLY reason it differs from the no-DAC version: the terminal half-life runs roughly 6 to 8 days instead of minutes, so a single dose produces a sustained rise in GH and IGF-1 rather than a discrete pulse. Phase 1 human dosing studies used single subcutaneous doses of about 30 to 250 mcg/kg. Development was discontinued and it is NOT approved by any regulator; consumer supply is research-chemical grade. Because exposure is continuous rather than pulsatile, it is the less physiologic of the two CJC-1295 forms and carries more of the water-retention and glucose signal.

Ipamorelin

Selective ghrelin receptor (GHS-R1a) agonist that triggers a growth hormone pulse with little effect on cortisol or prolactin, which is the main reason it is chosen over hexarelin or GHRP-6. Published human work is limited to small early-phase and post-operative ileus studies; development was discontinued and it is NOT an approved medicine anywhere. Everything sold to consumers is research-chemical grade, so the community 100-300 mcg per dose range comes from practice rather than from a label.

Side by side

The numbers

CJC-1295 with DAC compared with Ipamorelin
Attribute	CJC-1295 with DAC	Ipamorelin
Class	GH secretagogue	GH secretagogue
Routes	Subcutaneous	Subcutaneous
Dose range	1 mg–2 mg (typical 1.5 mg)	100 mcg–300 mcg (typical 200 mcg)
Frequency	Once a week	Once daily
Half-life	7 days	2 h
Cycle length	12 weeks	12 weeks
Experience	Intermediate	Beginner
Evidence	Limited human data	Limited human data
Contraindications	Pregnant / nursing Active malignancy Under 18	Pregnant / nursing Active malignancy Under 18
Side effects	Water retention and puffiness, more pronounced than with short-acting GHRHs Injection site redness or swelling Head rush, flushing or transient dizziness Tingling or numbness in the hands, which can reflect carpal tunnel pressure Reduced insulin sensitivity and higher fasting glucose with sustained elevation Lethargy or headache, often reported in the first week	Injection site redness or itching Head rush or flushing shortly after injection Water retention and morning puffiness Tingling or numbness in the hands, which can reflect carpal tunnel pressure Vivid dreams or grogginess when dosed pre-bed

Turn a typical dose into a mark on the syringe: CJC-1295 with DACIpamorelin

Goals

Where they overlap, and where they do not

Goal	CJC-1295 with DAC	Ipamorelin
muscle growth	CJC-1295 with DAC: 4/5	Ipamorelin: 3/5
recovery and sleep	CJC-1295 with DAC: 3/5	Ipamorelin: 4/5
injury repair	CJC-1295 with DAC: 3/5	Ipamorelin: 3/5
fat loss	CJC-1295 with DAC: 2/5	Ipamorelin: 2/5
longevity	CJC-1295 with DAC: 2/5	Ipamorelin: 2/5

They overlap on 5 goals and diverge on 0. Weights are this site’s editorial priority score out of 5 — how central a goal is to why people use a compound. They are not effect sizes and two 5s do not mean two equal results.

Go deeper

MonographCJC-1295 with DACMechanism, protocol, storage, sources.MonographIpamorelinMechanism, protocol, storage, sources.ToolReconstitution calculatorTurn either dose above into a mark on the syringe.

Other comparisons with these two

Educational information only, not medical advice. Talk to a licensed clinician before starting, changing, or stopping anything.